New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.

Global survey data highlight persistent stigma and self-management barriers for adults with diabetes in the workplace, with implications for clinical care.

The FDA approves a single monthly injection of mirikizumab-mrkz for ulcerative colitis, enhancing patient convenience and addressing bowel urgency effectively.

Patient preferences favor home-based tests but MDs do not, while cost barriers significantly impact follow-up completion, according to the 2 new analyses.

These 42 factors that affect blood glucose are in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.

Panelists discuss how vasomotor symptoms undermine physical comfort, sleep, and long-term health, emphasizing integrative management to restore overall quality of life.

Panelists discuss how hormonal decline and KNDy neuron overactivation drive vasomotor symptoms and inform the development of targeted neurokinin receptor therapies.

Your daily dose of the clinical news you may have missed.

Women experience greater CR mortality benefits than men yet have 36% lower enrollment. New AHA statement addresses barriers across the care continuum.

Lisa Larkin, MD, discusses how elinzanetant may change menopause management for women who can’t use hormone therapy and what PCPs need to know.